Navigation Links
Renhuang Pharmaceuticals Announces Plans to Introduce Qing Re Jie Du Oral Liquid
Date:4/29/2010

HARBIN, China, April 29 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced the Company plans to launch Qing Re Jie Du Oral Liquid ("Qing"), a traditional Over-the-Counter ("OTC") Chinese Medicine for the treatment of influenza ("the flu") and upper respiratory infections in June 2010.

Qing is an all-natural, plant-based traditional OTC Chinese Medicine with proven benefits in treating the flu, upper respiratory infections, and sore throats. The Company expects Qing to generate $1.0 million to $1.5 million in revenues in fiscal 2010.

"We have great confidence in the performance and effectiveness of our latest product, Qing Re Jie Du Oral Liquid, and anticipate positive market acceptance," said Mr. Shaoming Li, the Chairman and CEO of Renhuang. "Qing's all-natural active ingredients are effective against flu symptoms and cause no side effects associated with chemical drugs. At Renhuang, we are committed to developing superior products which meet the needs of our customers and we are equally committed to creating value for our shareholders. In this pursuit, we continue to expand our product portfolio to boost our revenue stream and fuel Renhuang's growth."

ABOUT RENHUANG PHARMACEUTICALS, INC.

Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. Company Website: http://www.renhuang.com

Safe Harbor Statement

This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to achieve its revenue and growth forecast for Qing Re Jie Du Oral Liquid, the Company's ability to achieve its financial guidance, ability to continue to improve its days sales outstanding, ability to list its shares on a senior stock exchange, ability to manage expansion of its operations effectively, competition in the marketing and sales of its products, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.

    Company Contact:

    Renhuang Pharmaceuticals, Inc.
     Ms. Portia Tan, IR Contact
     Tel:   +86-451-5392-5461
     Email: ir@renhuang.com

    CCG Investor Relations:
     Ms. Lei Huang, Account Manager
     Tel:   +1-646-833-3417 (New York)
     Email: lei.huang@ccgir.com
     Web:   www.ccgirasia.com

     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915 (New York)
     Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE Renhuang Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Renhuang Appoints New Director and Establishes Nominating and Compensation Committee
2. Renhuang Pharmaceuticals Announces Continual Improvement in Days Sales Outstanding
3. Renhuang Schedules Conference Call to Discuss FY 2010 First Quarter Results
4. Renhuang Announces Price Increase on Shengmai Granules
5. Renhuang Announces Fiscal Year 2010 Guidance
6. Jazz Pharmaceuticals to Announce First Quarter 2010 Financial Results on May 5, 2010
7. Cumberland Pharmaceuticals Partners in Canada With Alveda Pharmaceuticals to Commercialize Caldolor(R)
8. Onyx Pharmaceuticals Announces First Quarter 2010 Financial Results Teleconference and Webcast
9. Jazz Pharmaceuticals to Present at Deutsche Banks 35th Annual Health Care Conference
10. Anthera Pharmaceuticals to Present at Deutsche Bank Securities 35th Annual Health Care Conference
11. Isis Pharmaceuticals to Discuss Its Metabolic Franchise in a Conference Call on Wednesday, April 28
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... Calif. , March 1, 2017   Sun Chlorella ... about all things chlorella, is pleased to announce Non-GMO Project ... premium chlorella powder. Just in time for the ... in Anaheim, CA , Sun Chlorella Corp. ... all chlorella products, including: Sun Chlorella ...
(Date:3/1/2017)... 2017  Integrated Modular Design (IMD), a ... implementation of pre-fabricated healthcare products like bathroom ... seeks to lead the construction industry toward ... Fueled by their leading-edge pre-fabrication solutions, ... construction timelines and project risk, and increasing ...
(Date:3/1/2017)... 1, 2017  Global biotherapeutics leader CSL Behring ... ever Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) trial, known as ... reatment with H izentra ® ).  The Phase ... safety and tolerability of two different doses of CSL ... Subcutaneous [Human]), compared with placebo, in the maintenance treatment ...
Breaking Medicine Technology:
(Date:3/1/2017)... ... March 01, 2017 , ... ... permanently embedded anti-odor solution to cotton knit and woven fabrics. , Retail ... maintaining the luxurious look and feel of cotton. Cotton Incorporated has developed ...
(Date:3/1/2017)... HILLS, CA (PRWEB) , ... March 01, 2017 , ... ... cryoablation for the treatment of early stage breast cancer and where it fits in ... Genes & The Choices We Make .” The event brings together leading cancer and ...
(Date:3/1/2017)... ... March 01, 2017 , ... Expert on international living and leading a ... & Go. , Time & Go app is the ultimate strategic compass that helps ... time management methods enable people to work smarter, not harder, that's why Time & ...
(Date:3/1/2017)... York, NY & Greenwich, CT (PRWEB) , ... March 01, 2017 ... ... many runners, especially in the winter months when people don’t want to stop training ... the knees – and setting the treadmill to a small incline can help protect ...
(Date:3/1/2017)... ... March 01, 2017 , ... “McFarnia”: a suspenseful tale of ... truth about his life and mysterious disappearance. “McFarnia” is the creation of published author ... North Carolina. He currently serves as a Chaplain with Transport for Christ at a ...
Breaking Medicine News(10 mins):